Literature DB >> 12679224

Experimental aortic valve stenosis in rabbits.

Marie-Claude Drolet1, Marie Arsenault, Jacques Couet.   

Abstract

OBJECTIVES: We studied a known rabbit model of atherosclerosis to assess the effect of a hypercholesterolemic diet on aortic valve morphology and function. We also evaluated the effects of the combination of this diet with vitamin D supplements on the development of the disease and the occurrence of valve calcification.
BACKGROUND: Aortic valve stenosis (AVS) is the most common valvular heart disease. Recent observations have suggested a link between atherosclerosis and the development of AVS. However, until now, there has been no solid direct proof of this potential link.
METHODS: Rabbits were divided in three groups: 1) no treatment; 2) cholesterol-enriched diet (0.5% cholesterol); and 3) cholesterol-enriched diet plus vitamin D(2) (50,000 IU/day). Echocardiographic assessment of the aortic valve was done at baseline and after 12 weeks of treatment. The aortic valve area (AVA) and maximal and mean transvalvular gradients were recorded and compared over time.
RESULTS: Control animals displayed no abnormalities of the aortic valve. Despite important increases in blood total cholesterol levels, animals in group 2 did not develop any significant functional aortic valve abnormality over 12 weeks. However, eight of 10 of the animals in group 3 developed a significant decrease in AVA (p = 0.004) and significant increases in transvalvular gradients (p = 0.003).
CONCLUSIONS: This study supports a potential link between atherosclerosis and the development of AVS. The differences noted between hypercholesterolemic animals with or without vitamin D(2) supplementation imply a significant role of calcium in the development of AVS, meriting further attention.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12679224     DOI: 10.1016/s0735-1097(03)00090-1

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  35 in total

1.  Targeted therapy to prevent progression of calcific aortic stenosis.

Authors:  Nalini M Rajamannan; Catherine M Otto
Journal:  Circulation       Date:  2004-09-07       Impact factor: 29.690

2.  Risk factors for progression of calcific aortic stenosis and potential therapeutic targets.

Authors:  Ashvin R Kamath; Ramdas G Pai
Journal:  Int J Angiol       Date:  2008

3.  Is it time for medical therapy for aortic valve disease?

Authors:  Nalini M Rajamannan
Journal:  Expert Rev Cardiovasc Ther       Date:  2004-11

4.  Calcific aortic stenosis: a disease ready for prime time.

Authors:  Nalini M Rajamannan
Journal:  Circulation       Date:  2006-11-07       Impact factor: 29.690

Review 5.  Fibrocalcific aortic valve disease: opportunity to understand disease mechanisms using mouse models.

Authors:  Robert M Weiss; Jordan D Miller; Donald D Heistad
Journal:  Circ Res       Date:  2013-07-05       Impact factor: 17.367

6.  Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis.

Authors:  Luis M Moura; Sandra F Ramos; José L Zamorano; Isabel M Barros; Luis F Azevedo; Francisco Rocha-Gonçalves; Nalini M Rajamannan
Journal:  J Am Coll Cardiol       Date:  2007-01-22       Impact factor: 24.094

Review 7.  Mineral metabolism and cardiovascular disease in CKD.

Authors:  Hideki Fujii; Nobuhiko Joki
Journal:  Clin Exp Nephrol       Date:  2017-01-06       Impact factor: 2.801

Review 8.  Quantitative cardiovascular magnetic resonance for molecular imaging.

Authors:  Patrick M Winter; Shelton D Caruthers; Gregory M Lanza; Samuel A Wickline
Journal:  J Cardiovasc Magn Reson       Date:  2010-11-03       Impact factor: 5.364

Review 9.  Molecular mechanisms underlying the onset of degenerative aortic valve disease.

Authors:  Daihiko Hakuno; Naritaka Kimura; Masatoyo Yoshioka; Keiichi Fukuda
Journal:  J Mol Med (Berl)       Date:  2008-09-03       Impact factor: 4.599

10.  ACE inhibition attenuates uremia-induced aortic valve thickening in a novel mouse model.

Authors:  Mikko A Simolin; Tanja X Pedersen; Susanne Bro; Mikko I Mäyränpää; Satu Helske; Lars B Nielsen; Petri T Kovanen
Journal:  BMC Cardiovasc Disord       Date:  2009-03-03       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.